Key Takeaways
- Inhibrx Biosciences reported an Objective Response Rate (ORR) of 42.5% for its INBRX-106 and pembrolizumab combination in head and neck cancer.
- The company's stock, $INBX, surged 68.3% to $38.50 in early trading following the announcement.
- This positive data significantly de-risks the INBRX-106 program, potentially paving the way for accelerated approval pathways and substantial market penetration.
- The strong response rate could position INBRX-106 as a frontrunner in the challenging head and neck cancer therapeutic landscape.
- Investors will now closely monitor Inhibrx's regulatory interactions and potential partnership discussions following this significant clinical milestone.
Inhibrx Surges on Promising Cancer Drug Results
Inhibrx Biosciences announced positive interim Phase 2 results for its investigational CD47-targeting therapeutic INBRX-106, combined with Merck’s anti-PD-1 therapy pembrolizumab ($MRK), in patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC). The trial, evaluating 40 patients, demonstrated an Objective Response Rate (ORR) of 42.5% (17 complete or partial responses) as of the data cutoff on May 20, 2024, significantly exceeding expectations for this difficult-to-treat population. The median Duration of Response (DoR) has not yet been reached, with responses ongoing for up to 14 months.
Following the news, Inhibrx shares ($INBX) experienced an immediate and dramatic spike, opening 68.3% higher at $38.50 on Tuesday, adding approximately $1.1 billion to its market capitalization. Trading volume soared to over 15 million shares within the first hour, compared to its 30-day average of just 750,000 shares, indicating strong investor confidence and a rapid re-rating of the company's pipeline prospects. The surge marked a new 52-week high for the stock, surpassing its previous peak of $28.15 set in February 2024.
Market Impact
The substantial jump in $INBX shares to $38.50 represents the largest single-day percentage gain for the company since its initial public offering in 2020. This move catapulted Inhibrx's market valuation to approximately $2.7 billion, placing it firmly among mid-cap biotechs with a promising clinical-stage asset. The impressive ORR of 42.5%, particularly in a heavily pre-treated HNSCC cohort where standard therapies often yield ORRs in the 15-25% range, suggests a potential best-in-class profile for the INBRX-106 combination.
The positive data has also sent ripples across the broader oncology biotech sector, particularly for companies developing CD47 inhibitors or novel combination immunotherapies. While $MRK itself saw a modest increase of 0.8% to $129.10, reflecting the incremental benefit to its established Keytruda franchise, the market is now scrutinizing other CD47 developers for potential read-throughs. Companies like Gilead Sciences ($GILD), which is developing magrolimab, and Forty Seven (acquired by $GILD), have previously highlighted the potential of CD47 inhibition, but also the challenges, including hematologic toxicities. Inhibrx's reported manageable safety profile, with primarily Grade 1/2 hematologic adverse events and no new safety signals attributable to INBRX-106, further distinguishes its asset.
What Analysts Are Saying
"This interim Phase 2 data for INBRX-106 is a game-changer for Inhibrx, significantly de-risking the asset and opening up multiple strategic avenues," commented Dr. Emily Chen, a senior biotech analyst at SVB Leerink. "An ORR of 42.5% in HNSCC, especially with an encouraging safety profile and duration of response, positions this combination as potentially superior to existing standards and other investigational therapies. We are upgrading our price target on $INBX to $55, reflecting increased probability of success and a larger market opportunity."
Conversely, some analysts adopt a more cautious stance, emphasizing the relatively small sample size of the interim analysis. "While the data is undoubtedly promising, it's crucial to remember this is an interim readout from a Phase 2 trial," stated Mark Thompson, a portfolio manager specializing in healthcare at Citadel. "The full dataset, including longer-term follow-up and a larger patient cohort, will be necessary to fully confirm these efficacy signals and solidify the safety profile. Competition in HNSCC is also fierce, with multiple PD-1/PD-L1 combinations and emerging therapies. We'll be looking for confirmation of these results in a registrational trial before making a definitive bullish call."
What to Watch
Investors should closely monitor several key catalysts and data points in the coming months. Inhibrx is expected to present the complete Phase 2 data at a major medical conference, such as ASCO or ESMO, in late 2024 or early 2025, which could provide further detail on secondary endpoints like progression-free survival (PFS) and overall survival (OS). The company's upcoming end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) will be critical for determining the regulatory pathway, with the possibility of accelerated approval given the high unmet medical need in HNSCC.
Attention will also turn to potential partnership or acquisition discussions. The robust data could make Inhibrx an attractive target for larger pharmaceutical companies looking to bolster their oncology pipelines, particularly given the complementary nature of INBRX-106 to existing immune checkpoint inhibitors. Key resistance levels for $INBX shares could be tested at $40.00 and $45.00 in the near term, while strong support is likely to be found around the pre-announcement close of $22.88. Any unforeseen safety issues in the full dataset or a more challenging-than-expected regulatory path could pose significant downside risks to the current valuation.
